Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-03-26 Legal Proceedings Report
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
First iSCIB1+ patient dosed
Legal Proceedings Report Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an announcement dated March 26, 2024, regarding an 'Update on SCOPE trial' where the first patient was dosed. It includes commentary from the CEO and medical professionals, details about the drug (iSCIB1+), trial timelines (Q3 2024 recruitment completion, Q4 2024 early data), and contact information typical of a regulatory news service release. The presence of 'RNS Number', 'National Storage Mechanism', and the closing statement referencing 'RNS, the news service of the London Stock Exchange' strongly indicates this is a general regulatory announcement that does not fit the more specific categories like 10-K, ER, or IR. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6324 chars) is substantial enough that it is the primary announcement, not just a brief notice about a report.
2024-03-26 English
Appointment of Sath Nirmalananthan to the Board
Board/Management Information Classification · 99% confidence The document is clearly identified as an 'RNS Number' release from 'Scancell Holdings Plc' dated '14 March 2024'. The content announces the 'Appointment of Sath Nirmalananthan to the Board of Directors', detailing his background and new role. This type of announcement, concerning changes in senior management or the board, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content dictates the MANG classification over the general RNS fallback.
2024-03-14 English
Scancell Attendance at Upcoming Conferences
Regulatory Filings Classification · 99% confidence The document is identified by the presence of an 'RNS Number' and the explicit mention of 'RNS Number : 4269G' and 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This indicates it is a general regulatory announcement or press release distributed via the RNS system. The content details the company's attendance at upcoming conferences, which is an informational update rather than a core financial report (like 10-K, IR, ER) or a specific corporate action filing (like DIV, CAP, DIRS). Since it is a general regulatory announcement that doesn't fit the highly specific categories, the fallback category 'Regulatory Filings' (RNS) is the most appropriate classification.
2024-03-12 English
Presenting at Next-Gen Immuno-Oncology Conference
Regulatory Filings Classification · 100% confidence The document is a short announcement (4497 characters) released via RNS (the news service of the London Stock Exchange), indicated by the 'RNS Number' header and the concluding boilerplate text mentioning RNS and the FCA. The content announces that the company will be presenting at an external conference ('Next-Gen Immuno-Oncology Conference') and provides details about the presentation time and speaker. This is not a full financial report (like 10-K or IR), nor is it a specific regulatory filing like a Director's Dealing (DIRS) or a Dividend Notice (DIV). Since it is a general, time-sensitive corporate update distributed through the official regulatory news service that doesn't fit a more specific category, it falls best under the general 'Regulatory Filings' fallback category (RNS), or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a report, but here it announces participation in an event. Given the context of RNS distribution for general corporate news, RNS is the most appropriate general classification.
2024-03-04 English
Change of Auditor
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a formal announcement dated February 20, 2024, regarding a 'Change of Auditor' for Scancell Holdings Plc. This type of announcement, which details administrative or corporate governance changes (like auditor appointment/resignation) and is distributed via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Auditor Change'. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the source (RNS Number) and the nature of the announcement, RNS is the most appropriate classification.
2024-02-20 English
Directorate Change
Board/Management Information Classification · 100% confidence The document is an official announcement filed via RNS (RNS Number : 9423B) on February 5, 2024. The primary content details a 'Directorate Change and Appointment of Head of Development,' specifically the retirement of an Executive Director and the appointment of a new Head of Development. This directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content is about management changes, making MANG the most precise classification over the general RNS fallback.
2024-02-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.